It is common practice in many ophthalmic units to administer multiple applications of 10% phenylephrine in combination with an anti-cholinergic agent to ensure adequate pupil mydriasis prior to routine cataract surgery. Phenylephrine is a pure a-I adrenoreceptor agonist known to produce marked systemic vasocon striction and associated hypertension with occasional profound reflex bradycardia. Many reviews have suggested caution in the use of 10% phenylephrine in the elderly or hypertensive patient. In a prospective, randomised trial we have assessed pupil dilation comparing the efficacy of 10% phenylephrine (53 patients) versus 2.5% phenylephrine (62 patients). When administered in conjunction with 1% cyclopen tolate four times over 1 hour pre-operatively, 2.5% phenylephrine was found to be as effective as 10% phenylephrine in the initiation and maintenance of mydriasis during both extracapsular and phacoemulsi fication cataract extraction.
SUMMARY
It is common practice in many ophthalmic units to administer multiple applications of 10% phenylephrine in combination with an anti-cholinergic agent to ensure adequate pupil mydriasis prior to routine cataract surgery. Phenylephrine is a pure a-I adrenoreceptor agonist known to produce marked systemic vasocon striction and associated hypertension with occasional profound reflex bradycardia. Many reviews have suggested caution in the use of 10% phenylephrine in the elderly or hypertensive patient. In a prospective, randomised trial we have assessed pupil dilation comparing the efficacy of 10% phenylephrine (53 patients) versus 2.5% phenylephrine (62 patients). When administered in conjunction with 1% cyclopen tolate four times over 1 hour pre-operatively, 2.5% phenylephrine was found to be as effective as 10% phenylephrine in the initiation and maintenance of mydriasis during both extracapsular and phacoemulsi fication cataract extraction.
Phenylephrine acts almost exclusively as a direct a-1 adrenoreceptor agonist and is routinely used to ensure effective pre-operative mydriasis in cataract surgery. In our experience the 10% solution of phenylephrine (Minims) is commonly administered in conjunction with an anti-cholinergic agent (e.g. 1 % cyclopentolate) on four occasions over 1 hour pre-operatively. This combination of drugs is thought to ensure maximal stimulation of dilator pupillae while paralysing constrictor pupillae, in the hope of maintaining mydriasis throughout cataract extraction and lens implantation.
, The British National Formular/ recommends caution in the use of 10% phenylephrine in elderly patients and those with hypertension. The AssociaCorrespondence to: Mr A. G. Casswell, Sussex Eye Hospital, Eastern Road, Brighton, E. Sussex BN2 5BF, UK.
tion of British Pharmaceutical Industries? in describ ing the product licence for phenylephrine, states that the 10% phenylephrine solution is contraindicated in the elderly and in the hypertensive patient even if normotensive on medication. The maximum recom mended dose in any patient is one drop per hour.
Our intention in this study was to assess whether the use of 2.5% phenylephrine in pupil dilation prior to routine cataract surgery resulted in a less effective initiation or maintenance of mydriasis per-opera tively when compared with the 10% phenylephrine solution.
PATIENTS AND METHODS
One hundred and fifteen patients were operated on by one of four consultant surgeons over a 10 day period as part of a waiting list initiative. Patients presenting for surgery were pre-selected to exclude those with a history of ocular inflammation, pupil abnormality or previous surgery to that eye. All patients in this study were of Caucasian origin with mean age of 77.7 years (range 57-94 years).
All patients received four standard 'Minim' drops of both aqueous phenylephrine and 1 % cyclopento late during the 1 hour preceding surgery. Patients were randomised to receive either 10% phenyl ephrine (53 patients) or 2.5% phenylephrine (62 patients). Surgery was carried out after peribulbar anaesthesia using a combination of lignocaine, bupivacaine and sodium hyaluronidase. Every patient undergoing phacoemulsification had adrena line 1:1 000 000 added to the irrigation fluid used per operatively (Table I) . Adrenaline was not added to the infusion fluid of those patients undergoing extracapsular cataract extraction.
All pupil measurements were made by the surgeon with callipers viewed through the operating micro scope. The surgeon· measuring the pupil diameter Eye (1996) 10, 95-98 © 1996 Royal College of Ophthalmologists was not aware of the pre-operative mydriatic drop regime used. Pupil measurements were made imme diately before surgery and then repeated following aspiration of lens cortex immediately prior to insertion of the intraocular lens into the capsular bag. Table II presents results for mean pre-operative pupil diameter and mean decrease in per-operative pupil diameter. The mean pre-operative pupil diameter achieved in the group of patients receiving 2.5% phenylephrine was 8.0 mm and in those receiving 10% phenylephrine was 8.2 mm. The mean decrease in pupil size per-operatively is
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Pre-operative pupil diameter (mm) (c) The number of patients failing to achieve or maintain a pupil diameter of 6 mm is also shown in Table II . A slightly greater number of patients in the 2.5% phenylephrine group failed to achieve or maintain a pupil diameter of 6 mm. When analysed using the chi-squared test no statistically significant difference was found between the 10% phenylephr ine and 2.5 % phenylephrine groups (p<0.05).
DISCUSSION
In a randomised, prospective trial we have demon strated that there appears to be no significant difference in the ability of 2.5% and 10% phenyl ephrine to initiate and maintain pupil mydriasis in both phacoemulsification and extracapsular methods of uncomplicated cataract extraction and lens implantation.
Phacoemulsification causes less operative miosis than extracapsular surgery but it was not determined in this trial whether this was due to decreased iris Pre-operative pupil diameter (mm)
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Pre-operative pupil diameter (mm) (d) trauma, in particular the avoidance of nucleus expression, or the routine use of adrenaline in the infusion fluid during phacoemulsification -which has been demonstrated elsewhere to maintain mydriasis during cataract extraction ? A pupil diameter of 6 mm was considered a clinically relevant size, suitable for comparison of results between the two groups, since below this diameter it becomes impossible to perform a continuous curvilinear capsulorhexis of 6 mm under direct vision. A measured capsulorhexis diameter of 6 mm is subject to corneal magnification and approximates to an actual diameter of 5.0-5.5 mm. We feel this is the minimum size required to facilitate insertion of a non-foldable 5.5 mm intraocular lens as used in phacoemulsification.
Systemic absorption of many drugs applied topi cally to the conjunctival sac is known to occur via both the conjunctival capillaries and, after passage through the nasolacrimal duct, the nasal mucosa. 4 The predominant a-agonist action of phenylephrine causes a generalised peripheral vasoconstriction with associated elevation of systemic blood pressure and occasionally a marked reflex bradycardia. Many reports exist of adverse systemic reactions to topical 10% phenylephrine through its action on the cardiovascular system, and a few reports exist of cardiovascular reactions to 2.5% phenylephrine. 5 A review of reported adverse reactions by Fraunfelder et al. 6 identified 39 cases of significant reactions to 10% phenylephrine including 15 myo cardial infarctions, 11 of which were fatal. Although no proven causal relationship was demonstrated, both the authors and the surgeons who reported the individual cases felt that there was a high probability of the use of 10% phenylephrine contributing to the subsequent cardiovascular event reported. Most adverse reactions occurred approximately 20 minutes after application of the phenylephrine. Other case reports of adverse reactions to 10% phenylephrine include hypertension and cerebrovascular acci dents, 7 -10 ventricular arrhythmia ll and sub-arach noid haemorrhage Y A single 'Minim' eye drop (approx. 35-50 J-LI) of 10% phenylephrine contains at least 3.5 mg of active drug (Chauvin Pharmaceuticals Ltd). If used in the treatment of acute hypotension the upper limit of safety for a systemic dose of phenylephrine, in a young adult, has been reported as 1.5 mg by slow intravenous infusion or 10 mg subcutaneously ? , 13 Drugs applied to the conjunctiva are thought to be systemically absorbed almost as rapidly as the equivalent dose given intravenously. Therefore the routine application of four drops of 10% phenyl ephrine can potentially result in an elderly person receiving up to 9 times the maximum recommended dose of phenylephrine for a young adult. Plasma drug levels following topical administration have been measured by Kumar et al. 14 and found to be significantly higher at 20 minutes following applica tion in those receiving 10% as opposed to 2.5% phenylephrine.
Extra caution is required in those taking tricyclic anti-depressants or monoamine-oxidase inhibitors since both drug types are known to potentiate the action of phenylephrine. The 10% phenylephrine solution also causes greater discomfort on applica tion than the 2.5% solution ? 5 A study by Duffin et al. 16 of 44 patients receiving 2.5% or 10% phenylephrine prior to extracapsular surgery demonstrated no significant difference in pre-operative mydriasis between the two concentra tions regardless of iris colour. This study did, however, find a significant increase in operative miosis in those patients with very darkly pigmented irises if 2.5% phenylephrine was used. Other studies l7 . I8 assessing pupil dilation for diagnostic purposes tend to support our findings, with no benefit being gained by the use of 10% as opposed to 2.5% phenylephrine. Most patients in our study were elderly Caucasians and it is possible that younger patients, particularly those with a heavily pigmented iris, would demonstrate a greater mydria tic response to the 10% phenylephrine solution.
The infrequency of reported reactions to 10% phenylephrine may be due partly to the fact that maximum plasma concentration of the drug following topical administration occurs 20 minutes after application and then decreases rapidly. 15 In our experience 20 minutes after application of phenylephrine drops, prior to cataract surgery, most patients would still be on the ophthalmic ward with a minimum of monitoring, allowing hypertensive reac tions to pass unnoticed. Phenylephrine also causes marked local vasoconstriction which helps to limit systemic absorption.
The use of topical 10% phenylephrine is already considered to be contraindicated in the newborn due to its systemic hypertensive action, 19 . 20 and we believe that its use is no longer justified on a routine basis in pupil dilatation prior to uncomplicated cataract surgery in the elderly. We suggest that the use of the commonly available 2.5% solution of aqueous phenylephrine allows a quarter of the potential systemic dose to be given with no sig nificant decrease in degree of mydriasis obtained in most cases.
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